Claudine Bae, NP
Nurse Practitioner · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Claudine Bae’s office at (650) 723-4000 to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$34,311
Medicare paid this office $34,311 for 196 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 96 | $13,713 | $95 |
| Long return visit (40+ min) | 42 | $9,114 | $136 |
| Long return visit (40+ min) | 30 | $5,540 | $111 |
| Return visit (30+ min) | 63 | $5,106 | $71 |
Who their Medicare patients are
196 Original Medicare patients in 2024. Average age 72 · Also on Medicaid 32% · Health risk score 1.77. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 70% · Cancer 54% · Diabetes 24% · Chronic kidney disease 18% · Coronary heart disease 17% · Atrial fibrillation 16% · Depression 16% · Heart failure 13% · COPD 8%.
The office billed $160,496, Medicare allowed $44,054 and paid $34,311; for 357 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 196 | 357 | 72 | 1.77 | $160,496 | $34,311 |
| 2023 | 44 | 718 | 76 | 2.10 | $65,993 | $23,838 |
| 2022 | 50 | 368 | 74 | 1.67 | $46,359 | $14,556 |
| 2021 | 84 | 178 | 71 | 1.16 | $30,241 | $11,906 |
| 2020 | 78 | 131 | 70 | 1.37 | $33,143 | $8,724 |
| 2019 | 256 | 1,818 | 67 | 1.45 | $353,624 | $52,709 |
| 2018 | 243 | 1,048 | 66 | 1.45 | $246,678 | $38,908 |
| 2017 | 90 | 246 | 65 | 1.46 | $53,216 | $9,511 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Return visit (30+ min) | 33 | $4,944 | $77 |
| New patient visit (45+ min) | 14 | $1,309 | $94 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 36 | $601 | $8 |
| Blood test, comprehensive group of blood chemicals | 27 | $435 | $10 |
| Insertion of needle into vein for collection of blood sample | 25 | $416 | $8 |
| Ferritin (blood protein) level | 13 | $214 | $13 |
| Cyanocobalamin (vitamin b-12) level | 14 | $207 | $15 |
| Transferrin (iron binding protein) level | 13 | $200 | $13 |
| Folic acid level, serum | 12 | $173 | $14 |
| Iron level | 13 | $101 | $6 |
| Lactate dehydrogenase (enzyme) level | 14 | $89 | $6 |
2022: 8 services
| Return visit (30+ min) | 21 | $2,588 | $89 |
| Long return visit (40+ min) | 14 | $1,485 | $99 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 25 | $313 | $8 |
| Blood test, comprehensive group of blood chemicals | 19 | $249 | $10 |
| Ferritin (blood protein) level | 12 | $201 | $13 |
| Transferrin (iron binding protein) level | 12 | $188 | $13 |
| Insertion of needle into vein for collection of blood sample | 26 | $104 | $3 |
| Iron level | 12 | $96 | $6 |
2021: 4 services
| Long return visit (40+ min) | 68 | $8,255 | $120 |
| Short return visit | 47 | $1,788 | $38 |
| Return visit (30+ min) | 13 | $1,101 | $85 |
| Insertion of needle into vein for collection of blood sample | 41 | $120 | $3 |
2020: 3 services
| Long return visit (40+ min) | 57 | $5,440 | $94 |
| Return visit (30+ min) | 40 | $2,724 | $68 |
| Short return visit (20+ min) | 16 | $209 | $13 |
2019: 7 services
| Short return visit (20+ min) | 238 | $34,418 | $43 |
| Testing for presence of drug, by chemistry analyzers | 116 | $12,672 | $63 |
| New patient visit (30+ min) | 32 | $2,209 | $69 |
| Aspiration and/or injection of fluid from large joint | 13 | $1,009 | $37 |
| Injection of drug or substance under skin or into muscle | 41 | $803 | $10 |
| Injection, ketorolac tromethamine, per 15 mg | 31 | $59 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 35 | $42 | None |
2018: 6 services
| Short return visit (20+ min) | 230 | $28,491 | $46 |
| Testing for presence of drug, by chemistry analyzers | 63 | $5,209 | $69 |
| New patient visit (30+ min) | 21 | $1,453 | $69 |
| Injection of drug or substance under skin or into muscle | 20 | $506 | $14 |
| Injection, ketorolac tromethamine, per 15 mg | 17 | $40 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $13 | None |
2017: 2 services
| Short return visit (20+ min) | 82 | $6,363 | $50 |
| Testing for presence of drug, by chemistry analyzers | 12 | $939 | $78 |
Medicaid work
$77,116 in 2019
Medicaid paid $77,116 for 3,297 billed services this clinician did in 2019, up to 174 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 1,916 | $65,719 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service | 616 | $7,286 |
| New patient visit (30+ min) | 59 | $2,499 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 106 | $1,442 |
| Injection, dexamethasone sodium phosphate, 1 mg | 46 | $90 |
| Injection, ketorolac tromethamine, per 15 mg | 57 | $80 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 211 | $0 |
| Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 286 | $0 |
| 2019 | 3,297 | 8 | 174 | $77,116 |
| 2018 | 1,372 | 4 | 81 | $43,707 |
See the largest Medicaid services in earlier years
2018
| Short return visit (20+ min) | 1,179 | $41,512 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service | 71 | $2,195 |
| Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 61 | $0 |
| Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 61 | $0 |
Drugs they prescribed that Part D paid
$648,469
Pharmacies billed $648,469 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 3% of their Part D prescriptions (13 of 388) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
295 generic and 93 brand-name prescriptions · $648,469 in drug cost · 20 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lynparza | 25 | $358,967 | $14,359 |
| Eliquis | 36 | $31,698 | $880 |
| Xarelto | 12 | $6,594 | $550 |
| Hydroxyurea | 39 | $1,083 | $28 |
| Ondansetron | 52 | $941 | $18 |
See all 9 drugs
| Lynparza | 25 | $358,967 | $14,359 |
| Eliquis | 36 | $31,698 | $880 |
| Xarelto | 12 | $6,594 | $550 |
| Hydroxyurea | 39 | $1,083 | $28 |
| Ondansetron | 52 | $941 | $18 |
| Gabapentin | 15 | $725 | $48 |
| Prochlorperazine Maleate | 25 | $256 | $10 |
| Anastrozole | 18 | $209 | $12 |
| Amlodipine Besylate | 13 | $19 | $1 |
Year by year
| 2024 | 388 | 144 | 3% (13) | 24% | $648,469 |
| 2023 | 415 | 129 | 5% (21) | 17% | $71,995 |
| 2022 | 215 | 83 | 6% (12) | 19% | $174,853 |
| 2020 | 158 | 80 | 20% (31) | None | $4,827 |
| 2019 | 3,055 | 608 | 56% (1,697) | 4% | $117,913 |
| 2018 | 3,329 | 699 | 55% (1,836) | 5% | $111,532 |
| 2017 | 1,056 | 309 | 63% (667) | 5% | $36,425 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Eliquis | 39 | $33,177 | $851 |
| Xarelto | 12 | $9,255 | $771 |
| Hydroxyurea | 66 | $2,445 | $37 |
| Anastrozole | 35 | $620 | $18 |
| Prochlorperazine Maleate | 26 | $456 | $18 |
| Omeprazole | 11 | $286 | $26 |
| Warfarin | 41 | $280 | $7 |
| Levothyroxine | 16 | $206 | $13 |
| Hydrocodone-Acetaminophen | 12 | $181 | $15 |
| Prednisone | 19 | $87 | $5 |
| Baclofen | 11 | $67 | $6 |
2022: 5 drugs
| Eliquis | 16 | $9,081 | $568 |
| Prochlorperazine Maleate | 32 | $908 | $28 |
| Hydroxyurea | 21 | $772 | $37 |
| Anastrozole | 14 | $317 | $23 |
| Prednisone | 11 | $95 | $9 |
2020: 3 drugs
| Gabapentin | 39 | $1,084 | $28 |
| Baclofen | 15 | $331 | $22 |
| Nortriptyline | 13 | $103 | $8 |
2019: 27 drugs
| Lyrica | 31 | $17,891 | $577 |
| Hydrocodone-Acetaminophen | 612 | $13,973 | $23 |
| Oxycodone-Acetaminophen | 347 | $12,054 | $35 |
| Gabapentin | 516 | $10,906 | $21 |
| Oxycontin | 13 | $7,954 | $612 |
| Oxycodone | 315 | $6,910 | $22 |
| Morphine Sulfate Er | 139 | $3,415 | $25 |
| Tizanidine | 131 | $3,329 | $25 |
| Diclofenac | 39 | $2,648 | $68 |
| Baclofen | 130 | $2,557 | $20 |
| Pregabalin | 22 | $2,020 | $92 |
| Morphine Sulfate | 46 | $1,484 | $32 |
| Nortriptyline | 114 | $1,212 | $11 |
| Fentanyl | 16 | $1,146 | $72 |
| Zonisamide | 42 | $1,142 | $27 |
| Tramadol | 113 | $997 | $9 |
| Ibuprofen | 55 | $722 | $13 |
| Cyclobenzaprine | 59 | $688 | $12 |
| Amitriptyline | 31 | $631 | $20 |
| Methadone | 56 | $627 | $11 |
| Duloxetine | 15 | $536 | $36 |
| Ibu | 31 | $358 | $12 |
| Meloxicam | 44 | $264 | $6 |
| Hydromorphone | 16 | $221 | $14 |
| Methocarbamol | 14 | $140 | $10 |
| Carisoprodol | 13 | $85 | $7 |
| Acetaminophen-Codeine | 12 | $80 | $7 |
2018: 30 drugs
| Lyrica | 36 | $17,465 | $485 |
| Hydrocodone-Acetaminophen | 563 | $14,146 | $25 |
| Oxycodone-Acetaminophen | 386 | $13,594 | $35 |
| Gabapentin | 566 | $13,134 | $23 |
| Oxycodone | 296 | $6,788 | $23 |
| Morphine Sulfate Er | 179 | $5,667 | $32 |
| Savella | 11 | $3,829 | $348 |
| Voltaren | 14 | $3,031 | $217 |
| Tizanidine | 131 | $2,884 | $22 |
| Lidocaine | 11 | $2,446 | $222 |
| Baclofen | 128 | $2,435 | $19 |
| Morphine Sulfate | 60 | $2,159 | $36 |
| Nortriptyline | 179 | $2,132 | $12 |
| Diclofenac | 20 | $1,869 | $93 |
| Duloxetine | 39 | $1,716 | $44 |
| Methadone | 127 | $1,698 | $13 |
| Zonisamide | 48 | $1,431 | $30 |
| Fentanyl | 20 | $1,421 | $71 |
| Tramadol | 129 | $1,264 | $10 |
| Celecoxib | 13 | $947 | $73 |
| Cyclobenzaprine | 40 | $705 | $18 |
| Hydromorphone | 36 | $432 | $12 |
| Ibu | 37 | $418 | $11 |
| Meloxicam | 44 | $359 | $8 |
| Ibuprofen | 23 | $275 | $12 |
| Acetaminophen-Codeine | 22 | $269 | $12 |
| Naproxen | 21 | $138 | $7 |
| Carisoprodol | 17 | $116 | $7 |
| Zolpidem | 14 | $97 | $7 |
| Clonidine | 11 | $61 | $6 |
2017: 19 drugs
| Oxycodone-Acetaminophen | 150 | $6,044 | $40 |
| Lyrica | 11 | $5,383 | $489 |
| Morphine Sulfate Er | 99 | $3,760 | $38 |
| Oxycodone | 128 | $2,981 | $23 |
| Hydrocodone-Acetaminophen | 145 | $2,363 | $16 |
| Voltaren | 12 | $1,984 | $165 |
| Gabapentin | 108 | $1,728 | $16 |
| Fentanyl | 17 | $1,297 | $76 |
| Methadone | 47 | $734 | $16 |
| Nortriptyline | 55 | $578 | $11 |
| Baclofen | 22 | $541 | $25 |
| Morphine Sulfate | 21 | $504 | $24 |
| Tizanidine | 24 | $475 | $20 |
| Duloxetine | 12 | $329 | $27 |
| Tramadol | 35 | $298 | $9 |
| Zonisamide | 17 | $270 | $16 |
| Hydromorphone | 15 | $172 | $11 |
| Zolpidem | 16 | $105 | $7 |
| Carisoprodol | 14 | $96 | $7 |
Money from drug and device companies
$559 in 2025
| 2025 | 5 | 8 | None | $559 |
| 2024 | 1 | 1 | None | $34 |
| 2023 | 9 | 16 | None | $515 |
| 2022 | 6 | 9 | None | $492 |
| 2021 | 1 | 2 | None | $39 |
| 2020 | 1 | 1 | None | $27 |
| 2019 | 1 | 2 | None | $33 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | None | $132 | 1 payment
|
| Inspire Medical Systems | Inspire | $130 | 1 payment
|
| Amarin Pharma | Vascepa | $118 | 1 payment
|
| Argenx US | Vyvgart | $90 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $89 | 4 payments
|
See all 8 published payments
| Merck Sharp & Dohme | Meals · 2025-10-17 | Keytruda | $19 |
| Merck Sharp & Dohme | Meals · 2025-08-22 | Keytruda | $18 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-16 | None | $132 |
| Inspire Medical Systems | Meals · 2025-06-18 | Inspire | $130 |
| Merck Sharp & Dohme | Meals · 2025-05-16 | Keytruda | $20 |
| Argenx US | Meals · 2025-04-16 | Vyvgart | $90 |
| Merck Sharp & Dohme | Meals · 2025-03-28 | Keytruda | $32 |
| Amarin Pharma | Meals · 2025-03-14 | Vascepa | $118 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $34
| Merck Sharp & Dohme | Lynparza | $34 | 1 payment
|
2023: $515
| AstraZeneca Pharmaceuticals LP | Imfinzi | $129 | 2 payments
|
| Lilly USA | None | $85 | 1 payment
|
| GlaxoSmithKline | Zejula | $75 | 4 payments
|
| Janssen Biotech | Darzalex | $70 | 1 payment
|
| Abbvie | Venclexta | $49 | 2 payments
|
| Boston Scientific | Wavewriter Alpha Prime 16 | $46 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $24 | 1 payment
|
| Seagen | Tukysa | $22 | 1 payment
|
| Celgene | Pomalyst | $15 | 1 payment
|
2022: $492
| Lilly USA | None | $206 | 2 payments
|
| Amgen | None | $99 | 1 payment
|
| Karyopharm Therapeutics | Xpovio | $97 | 1 payment
|
| Boston Scientific | General - Pain Management | $43 | 3 payments
|
| Abbvie | Venclexta | $32 | 1 payment
|
| Seagen | Tukysa | $15 | 1 payment
|
2021: $39
| Boston Scientific | Click | $39 | 2 payments
|
2020: $27
| Boston Scientific | Entrada | $27 | 1 payment
|
2019: $33
| Boston Scientific | Spectra Wavewriter | $33 | 2 payments
|
Professional record
- NPI
- 1437687837
- Licence
- CA 95026504, NV APRN002511
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- NV 1437687837
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 170300000X (170300000X); Federal specialty code 363LF0000X (363LF0000X); Federal specialty code 363LX0001X (363LX0001X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-05-30
- NPI last updated
- 2025-12-30
- NPI record certified
- 2025-12-30
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 8285 W Arby Ave Ste 100-B, Las Vegas, NV, 89113